FDA has shifted to stressing the abbreviated part of the biosimilar development pathway, assuring sponsors that they can limit their required clinical demonstration with early analytical work.
Agency officials said characterization data will play a significant role, rather than clinical evidence, in part because the purpose of a biosimilar development program is to establish a product’s similarity...